{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:23:51Z","timestamp":1791278631715,"version":"4.1.0"},"reference-count":22,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,10,1]]},"abstract":"<jats:p>We report a patient with Pompe disease who developed reversible nephrotic syndrome during prolonged, high-dose, experimental, enzyme replacement therapy with recombinant human acid \u03b1-glucosidase (rhGAA). Because of the development of antibodies to rhGAA and concomitant clinical decline, escalating doses of rhGAA were administered as part of an experimental immune tolerance regimen. Histologic evaluation of kidney tissue revealed glomerular deposition of immune complexes containing rhGAA itself, in a pattern of membranous nephropathy. To our knowledge, this is the first reported case of nephrotic syndrome occurring during enzyme replacement therapy. The nephrotic syndrome gradually resolved after the rhGAA dose was decreased, indicating that decreasing the antigenic load can ameliorate glomerular immune complex deposition associated with enzyme replacement in a highly sensitized patient.<\/jats:p>","DOI":"10.1542\/peds.2003-0988-l","type":"journal-article","created":{"date-parts":[[2004,10,13]],"date-time":"2004-10-13T18:57:26Z","timestamp":1097693846000},"page":"e532-e535","source":"Crossref","is-referenced-by-count":77,"title":["Nephrotic Syndrome Complicating \u03b1-Glucosidase Replacement Therapy for Pompe Disease"],"prefix":"10.1542","volume":"114","author":[{"given":"Tracy E.","family":"Hunley","sequence":"first","affiliation":[{"name":"Divisions of Pediatric Nephrology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyanira","family":"Corzo","sequence":"additional","affiliation":[{"name":"Division of Clinical Genetics, Children\u2019s Hospital, Boston, Massachusetts"},{"name":"Genzyme Corp, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Dudek","sequence":"additional","affiliation":[{"name":"Medical Genetics, Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Kishnani","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Amalfitano","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Tsong","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Richards","sequence":"additional","affiliation":[{"name":"Genzyme Corp, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John A.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Medical Genetics, Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee"},{"name":"Divisions of Pediatric Nephrology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Tiller","sequence":"additional","affiliation":[{"name":"Medical Genetics, Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,10,1]]},"reference":[{"key":"2021120906053401700_R1","doi-asserted-by":"crossref","unstructured":"Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med.\u20082001;344:182\u2013188","DOI":"10.1056\/NEJM200101183440304"},{"key":"2021120906053401700_R2","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Kopp JB, Austin HA III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA.\u20082001;285:2743\u20132749","DOI":"10.1001\/jama.285.21.2743"},{"key":"2021120906053401700_R3","doi-asserted-by":"crossref","unstructured":"Brady RO, Murray GJ, Oliver KL, et al. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics.\u20081997;100(6). Available at: www.pediatrics.org\/cgi\/content\/full\/100\/6\/e11","DOI":"10.1542\/peds.100.6.e11"},{"key":"2021120906053401700_R4","doi-asserted-by":"crossref","unstructured":"Brooks DA. Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab.\u20081999;68:268\u2013275","DOI":"10.1006\/mgme.1999.2894"},{"key":"2021120906053401700_R5","doi-asserted-by":"crossref","unstructured":"Richards SM. Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders. Clin Appl Immunol Rev.\u20082002;2:241\u2013253","DOI":"10.1016\/S1529-1049(02)00049-1"},{"key":"2021120906053401700_R6","doi-asserted-by":"crossref","unstructured":"Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med.\u20082001;345:9\u201316","DOI":"10.1056\/NEJM200107053450102"},{"key":"2021120906053401700_R7","doi-asserted-by":"crossref","unstructured":"Kakavanos R, Turner CT, Hopwood JJ, Kakkis ED, Brooks DA. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet.\u20082003;361:1608\u20131613","DOI":"10.1016\/S0140-6736(03)13311-9"},{"key":"2021120906053401700_R8","doi-asserted-by":"crossref","unstructured":"Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood.\u20081999;93:2081\u20132088","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088"},{"key":"2021120906053401700_R9","doi-asserted-by":"crossref","unstructured":"Ponce E, Moskovitz J, Grabowski G. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid \u03b2-glucosidase. Blood.\u20081997;90:43\u201348","DOI":"10.1182\/blood.V90.1.43"},{"key":"2021120906053401700_R10","doi-asserted-by":"crossref","unstructured":"Germain DP, Kaneski CR, Brady RO. Mutation analysis of the acid \u03b2-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase. Mutat Res.\u20082001;483:89\u201394","DOI":"10.1016\/S0027-5107(01)00232-9"},{"key":"2021120906053401700_R11","doi-asserted-by":"crossref","unstructured":"Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid \u03b1-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet Med.\u20082001;3:132\u2013138","DOI":"10.1097\/00125817-200103000-00008"},{"key":"2021120906053401700_R12","doi-asserted-by":"crossref","unstructured":"Van den Hout JMP, Kamphoven JHJ, Winkel LPF, et al. Long-term intravenous treatment of Pompe disease with recombinant human \u03b1-glucosidase from milk. Pediatrics.\u20082004;113(5). Available at: www.pediatrics.org\/cgi\/content\/full\/113\/5\/e448","DOI":"10.1542\/peds.113.5.e448"},{"key":"2021120906053401700_R13","doi-asserted-by":"crossref","unstructured":"van den Hout HMP, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics.\u20082003;112:332\u2013340","DOI":"10.1542\/peds.112.2.332"},{"key":"2021120906053401700_R14","unstructured":"Couser WG, Alpers CE. Membranous nephropathy. In: Neilson EG, Couser WG, eds. Immunologic Renal Diseases. Philadelphia, PA: Lippincott-Raven; 1997: 1027\u20131052"},{"key":"2021120906053401700_R15","doi-asserted-by":"crossref","unstructured":"Dixon F, Feldman J, Vasquez J. Experimental glomerulonephritis: the pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis. J Exp Med.\u20081961;113:899\u2013920","DOI":"10.1084\/jem.113.5.899"},{"key":"2021120906053401700_R16","doi-asserted-by":"crossref","unstructured":"Kakkis ED, McEntee MF, Schmidtchen A, et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med.\u20081996;58:156\u2013167","DOI":"10.1006\/bmme.1996.0044"},{"key":"2021120906053401700_R17","doi-asserted-by":"crossref","unstructured":"Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost.\u20082000;26:179\u2013188","DOI":"10.1055\/s-2000-9821"},{"key":"2021120906053401700_R18","doi-asserted-by":"crossref","unstructured":"DiMichele DM, Kroner BL. The North American immune tolerance registry: practices, outcomes, outcome predictors. Thromb Haemost.\u20082002;87:52\u201357","DOI":"10.1055\/s-0037-1612943"},{"key":"2021120906053401700_R19","doi-asserted-by":"crossref","unstructured":"Ewenstein BM, Takemoto C, Warrier I, Lusher J, Saidi P, Eisele J, Ettinger LJ, DiMichele D. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood.\u20081997;89:1115\u20131116","DOI":"10.1182\/blood.V89.3.1115"},{"key":"2021120906053401700_R20","doi-asserted-by":"crossref","unstructured":"Tengborn L, Hansson S, Fasth A, Lubeck P-O, Berg A, Ljung R. Anaphylactoid reactions and nephrotic syndrome: a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome of two brothers. Haemophilia.\u20081998;4:854\u2013859","DOI":"10.1046\/j.1365-2516.1998.00190.x"},{"key":"2021120906053401700_R21","doi-asserted-by":"crossref","unstructured":"Dharnidharka VR, Takemoto C, Ewenstein BM, Rosen S, Harris HW. Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Pediatr Nephrol.\u20081998;12:654\u2013657","DOI":"10.1007\/s004670050522"},{"key":"2021120906053401700_R22","doi-asserted-by":"crossref","unstructured":"Bolton-Maggs PHB, Pasi KJ. Haemophilias A and B. Lancet.\u20082003;361:1801\u20131809","DOI":"10.1016\/S0140-6736(03)13405-8"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/4\/e532\/1020283\/zpe0100400e532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/4\/e532\/1020283\/zpe0100400e532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:14:49Z","timestamp":1639095289000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/4\/e532\/73208\/Nephrotic-Syndrome-Complicating-Glucosidase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,1]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,10,1]]},"published-print":{"date-parts":[[2004,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2003-0988-l","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,1]]}}}